Non-invasive haemodynamic assessments using Innocor™ during standard graded exercise tests by Fontana, P et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Non-invasive haemodynamic assessments using Innocor™
during standard graded exercise tests
Fontana, P; Boutellier, U; Toigo, M
Fontana, P; Boutellier, U; Toigo, M (2009). Non-invasive haemodynamic assessments using Innocor™ during
standard graded exercise tests. European Journal of Applied Physiology:Epub ahead of print.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
European Journal of Applied Physiology 2009, :Epub ahead of print.
Fontana, P; Boutellier, U; Toigo, M (2009). Non-invasive haemodynamic assessments using Innocor™ during
standard graded exercise tests. European Journal of Applied Physiology:Epub ahead of print.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
European Journal of Applied Physiology 2009, :Epub ahead of print.
Non-invasive haemodynamic assessments using Innocor™
during standard graded exercise tests
Abstract
Cardiac output (Q) and stroke volume (V (S)) represent primary determinants of cardiovascular
performance and should therefore be determined for performance diagnostics purposes. Since it is
unknown, whether measurements of Q and V (S) can be performed by means of Innocor during standard
graded exercise tests (GXTs), and whether current GXT stages are sufficiently long for the
measurements to take place, we determined Q and V (S) at an early and late point in time on
submaximal 2 min GXT stages. 16 male cyclists (age 25.4 +/- 2.9 years, body mass 71.2 +/- 5.0 kg)
performed three GXTs and we determined Q and V (S) after 46 and 103 s at 69, 77, and 85% peak
power. We found that the rebreathings could easily be incorporated into the GXTs and that Q and V (S)
remained unchanged between the two points in time on the same GXT stage (69% peak power, Q: 18.1
+/- 2.1 vs. 18.2 +/- 2.3 l min(-1), V (S): 126 +/- 18 vs. 123 +/- 21 ml; 77% peak power, Q: 20.7 +/- 2.6
vs. 21.0 +/- 2.3 l min(-1), V (S): 132 +/- 18 vs. 131 +/- 18 ml; 85% peak power, Q: 21.6 +/- 2.4 vs. 21.8
+/- 2.7 l min(-1), V (S): 131 +/- 17 vs. 131 +/- 22 ml). We conclude that Innocor may be a useful device
for assessing Q and V (S) during GXTs, and that the adaptation of Q and V (S) to exercise-to-exercise
transitions at moderate to high submaximal power outputs is fast enough for 1 and 2 min GXT stage
durations.
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ABSTRACT 
Cardiac output (Q) and stroke volume (VS) represent primary determinants of cardiovascular performance and 
should therefore be determined for performance diagnostics purposes. Since it is unknown, whether 
measurements of Q and VS can be performed by means of Innocor™ during standard graded exercise tests 
(GXTs), and whether current GXT stages are sufficiently long for the measurements to take place, we 
determined Q and VS at an early and late point in time on submaximal 2 min GXT stages. 16 male cyclists (age: 
25.4 ± 2.9 y, weight: 71.2 ± 5.0 kg) performed 3 GXTs and we determined Q and VS after 46 and 103 s at 69%, 
77%, and 85% peak power. We found that the rebreathings could easily be incorporated into the GXTs and that 
Q and VS remained unchanged between the 2 points in time on the same GXT stage (69% peak power, Q: 18.1 ± 
2.1 vs. 18.2 ± 2.3 l·min-1, VS: 126 ± 18 vs. 123 ± 21 ml; 77% peak power, Q: 20.7 ± 2.6 vs. 21.0 ± 2.3 l·min-1, 
VS: 132 ± 18 vs. 131 ± 18 ml; 85% peak power, Q: 21.6 ± 2.4 vs. 21.8 ± 2.7 l·min-1, VS: 131 ± 17 vs. 131 ± 22 
ml). We conclude that Innocor™ may be a useful device for assessing Q and VS during GXTs, and that the 
adaptation of Q and VS to exercise-to-exercise transitions at moderate to high submaximal power outputs is fast 
enough for 1 and 2 min GXT stage durations. 
 
Keywords: performance diagnostics, cardiac functions, haemodynamics, steady state, graded exercise tests, 
inert gas rebreathing 
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INTRODUCTION 
Conventional cardiovascular performance diagnostics relies on heart rate, blood lactate concentration, perceived 
exertion, respiratory (oxygen consumption, carbon dioxide output), and ventilatory (breathing frequency, tidal 
volume) parameters. Changes in these parameters over time, in particular with respect to maximal oxygen 
consumption, are used to determine performance improvements after training. Nevertheless, (maximal) oxygen 
consumption does not constitute the primary determinant of cardiovascular performance. In fact, it is believed 
that in healthy humans, a high maximal oxygen consumption primarily depends on maximal oxygen delivery to 
the exercising muscles (Saltin and Calbet 2006), and therefore on a high, maximal cardiac output (Calbet et al. 
2004). Consequently, we propose that for performance diagnostics purposes, cardiac output and stroke volume 
should standardly be determined under exercise conditions and subsequently related to the conventional 
respiratory, ventilatory, and metabolic parameters. 
 
However, cardiac output and stroke volume determinations must meet several requirements in order to be viable 
for incorporation into standard exercise tests. A central requirement is, that the employed measurement method 
is valid, reliable, and safe. Furthermore, it should not pose any major discomfort to the participants. In addition, 
the employed method should be easily applicable to standard graded exercise test protocols (Bentley et al. 
2007). One promising non-invasive approach having the potential to fulfil these requirements is nitrous oxide 
(inert gas) rebreathing, which can be performed using the recently introduced Innocor™ system (Innovision, 
Odense, Denmark). Validation of the Innocor™ cardiac output measurement against direct Fick showed a good 
accordance (Agostoni et al. 2005, Gabrielsen et al. 2002, Peyton and Thompson 2004). In addition, we recently 
found that cardiac output determinations using Innocor™ are reliable (Fontana et al. 2009). While it was shown 
that cardiac output determinations by Innocor™ are valid and reliable, it is still unknown whether the 
measurement point in time during a typical graded exercise test stage (i.e., 2 min) affects the outcome of the 
cardiac output measurement in healthy participants, i.e. whether cardiac output differs if measured within the 
first minute after the exercise-to-exercise transitions compared to when measured at the end of the 2 min stages. 
Evidence for quick adjustments of cardiac output to increased power comes from the examination of 
haemodynamics during rest-to-exercise transitions in healthy participants by determining cardiac function on a 
beat-by-beat basis, using Doppler ultrasound (De Cort et al. 1991) or the model flow method (Lador et al. 2006, 
2008). These studies showed that when increasing power from rest to 50, 80, or 100 W (i.e., "rest-to-exercise" 
transitions), a steady state for cardiac output is quickly reached (e.g., within the first minute). However, all 
 4/16 
power outputs were not higher than 100 W, and only rest-to-exercise, but not exercise-to-exercise transitions 
were examined. Furthermore, these studies do not provide any information about intra-stage haemodynamics, 
i.e. the evolvement of cardiac output, stroke volume, and heart rate on the single stages of moderate and high 
submaximal power during standard graded exercise tests.  
 
Therefore, we aimed at determining cardiac output and stroke volume using inert gas rebreathing by means of 
Innocor™, as well as heart rate, during standard graded exercise tests after 46 and 103 s at 69, 77, and 85% peak 
power in healthy male participants. We hypothesised that these measurements are feasible for stage durations of 
2 min, and that on each test stage no differences with respect to cardiac output and stroke volume exist between 
the 2 points in time (46 and 103 s). 
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METHODS 
Participants 
We recruited 16 recreationally trained male cyclists. The participants' individual values are presented in Table 1. 
All participants were healthy and non-smoking. In order to avoid fatigue-related effects on test performance, no 
strenuous physical activity was allowed for 48 h prior to the tests. Starting 2 weeks before the examinations, the 
participants recorded their physical activity in a training log and continued to do so until the end of the study. 
Based on the training log, we observed that the training volume was similar throughout the study. We informed 
the participants about all procedures involved and about the associated risks. After the completion of a routine 
health questionnaire, the participants gave written informed consent. The study was approved by the human 
ethics committee of the ETH Zurich. 
Study design and experimental setup 
All participants performed 3 graded exercise tests to volitional exhaustion on a cycle ergometer (Ergoselect 
200K, Ergoline, Bitz, Germany). In all participants, test 1 (increments of 30 W every 2 min until volitional 
exhaustion) served for determining peak power and maximal gas exchange (Innocor™, Innovision, Odense, 
Denmark). During test 1, we also determined the freely chosen pedalling rate (≥ 70 min-1), which was then held 
constant throughout all tests. In tests 2 and 3, we non-invasively determined cardiac output by inert gas 
rebreathing (Innocor™, Innovision, Odense, Denmark) at 69, 77, and 85% peak power attained in test 1. The 
respective rebreathings were performed in a randomised order, either during the first or the second min on each 
stage  (either in test 2 or 3). Throughout tests 2 and 3, we continuously recorded heart rate and oxygen 
consumption. All tests took place within a time frame of 2 weeks, except for subject number 9, who was tested 5 
weeks apart, due to a common cold. 
On the first examination day, we informed the participants about the upcoming procedures. Then, they 
performed test 1. Test 2 was either carried out 1 h after test 1 or on day 2. Test 3 was always conducted on day 
2, either 1 h after test 2 or as the only test performed. Before tests 2 and 3, we equipped the participants with a 
heart rate monitor (S610i, Polar Electro, Kempele, Finland), a facemask (Hans Rudolph, Shawnee, KS, USA), 
and an anti-bacterial filter (PALL PF30-S, Pall, East Hills, NY, USA). We then connected the participants to the 
Innocor™ device. Before test 2, the participants practiced the rebreathing procedure with ambient air during 3 
attempts, as described earlier (Fontana et al. 2009). Subsequently, we measured cardiac output at rest. Two min 
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after the rebreathing under resting conditions, cycling started at 54% peak power for 2 min (“warm-up”). Then, 
we increased power to 69% peak power for 2 min. Afterwards, power was raised twice by 8 % peak power for 2 
min. Cardiac output determinations were performed at 69, 77, and 85% peak power. All measurements were 
performed by the same investigator.  
Determination of cardiac output 
Rebreathings were performed in a closed system, which consisted of a 3-way respiratory valve connecting a 
facemask, an anti-static rubber bag, and an infrared photoacoustic gas analyser (Clemensen et al. 1994). The 
participants rebreathed a gas mixture of nitrous oxide (0.5%) and sulphur hexafluoride (0.1%) in oxygen, diluted 
with atmospheric air, from an anaesthesia bag of size 3-6 l, depending on the individual participant's predicted 
vital capacity (Quanjer et al. 1993). At rest, the settings of the Innocor™ were a 20% bolus volume (volume of 
gas mixture, consisting of nitrous oxide, sulphur hexafluoride, and oxygen), a rebreathing frequency of 20 min-1, 
and a total gas mixture volume of 40% of the predicted vital capacity (Quanjer et al. 1993). The Innocor™ 
software adjusted these settings dynamically under exercise conditions, considering a maximal bolus volume of 
40%, a minimal oxygen content of 13%, and a maximal carbon dioxide content of 15%, taking into account the 
participants’ individual breathing frequencies. Rebreathing was typically performed over 5-8 breaths, of which 
the last 2-3 breaths were used for the calculation of pulmonary blood flow and cardiac output, taking into 
account estimated shunt flow (Gabrielsen et al. 2002). The calculation of cardiac output was performed 
according to the manufacturer. For detecting the single breaths during the rebreathings, we standardly used end-
tidal carbon dioxide concentrations. This procedure has been shown to give reliable measurements of pulmonary 
blood flow and cardiac output, even at peak exercise (Fontana et al. 2009). However, during some rebreathings, 
the detection of the breaths was facilitated by using end-tidal oxygen concentrations. Using this procedure, all 
rebreathings could be used in order to calculate cardiac output. Each rebreathing lasted between 8 and 10 s. 
Since the mean transit time of a dye marker after 60 to 120 s of high intensity exercise appears to be in the range 
of 12 s (Krustrup et al. 2009), it is unlikely that recirculation of nitrous oxide occurred. Additionally, we 
checked online breath-by-breath rebreathing gas concentrations during each cardiac output measurement in 
order to detect possible elevations in nitrous oxide concentrations due to recirculating gas. We observed no 
nitrous oxide gas recirculation during all measurements. Thus, a recirculation-based measurement bias should 
be excluded. 
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Calculations 
For each participant, we calculated peak power as „power on the last completed stage + t (s) / 120 s · 30 W“. For 
peak oxygen consumption, we took the highest mean over 30 s achieved in test 1. During tests 2 and 3, the exact 
rebreathing points in time relative to test stage duration were calculated by determining the time point of the 
valve opening and adding the time elapsed until complete mixing of the rebreathing gases was achieved. 
Therefore, rebreathing points in time were on average 46 or 103 s either in test 2 or 3 on the 3 test stages (Table 
2). We calculated stroke volume by dividing cardiac output by heart rate. For heart rate, we took the 10 s mean 
recorded right after the rebreathings. 
Statistical analysis 
We checked the data for normality by Q-Q plot, and analysed it for statistical significance (P < 0.05) using 
SPSS 16.0 (SPSS, Chicago, IL, USA). For comparisons of cardiac output, stroke volume, and heart rate between 
46 and 103 s on each single stage, we used Student’s paired t-test. For comparisons between stages, ANOVA 
repeated measures with Bonferroni correction was used. Since we did not perform multiple comparisons, the 
occurrence of a type I error is unlikely and the aforementioned analyses were chosen instead of a 2-way 
ANOVA (time x stage).
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RESULTS 
Cardiac output 
Cardiac output measurements by Innocor™ inert gas rebreathing could be performed at 69, 77, and 85% peak 
power at both, 46 and 103 s after the stage transitions. Furthermore, cardiac output for the 16 participants did 
not differ between the early (46 s) and late (103 s) rebreathing points in time on all 3 test stages (69, 77, and 
85% peak power; Table 3, Fig. 1), and the adjustments of cardiac output between 46 and 103 s were the same 
after increments of 15 (from 54 to 69% peak power) and 8% peak power (from 69 to 77% and from 77 to 85% 
peak power; Table 3). Additionally, cardiac output increased significantly from rest to 69% of peak power at 46 
and 103 s (Table 3). Between 69 and 77% peak power, cardiac output further increased significantly with 
respect to both measurement points in time, whereas between 77 and 85% peak power, cardiac output was the 
same (Table 3). 
Stroke volume 
Stroke volume was not significantly different between the 2 measuring points in time at 69, 77, and 85% peak 
power (Table 3). Furthermore, stroke volume significantly increased when transitioning from rest to 69% peak 
power, both when measured at 46 and 103 s (Table 3). At 77 and 85% peak power, stroke volume was not 
different than at 69% peak power (Table 3). 
Heart rate 
Heart rate was significantly higher after 103 than after 46 s at 69% peak power (Table 3). Both, at 77 and 85% 
peak power, heart rate was not different between 46 and 103 s (Table 3). Heart rate rose from rest to 69%, 77%, 
and 85% peak power with respect to both measurement points in time (Table 3).  
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DISCUSSION 
In this study, we have shown that it is feasible to non-invasively determine cardiac output by inert gas 
rebreathing at 46 and 103 s on moderate and high intensity submaximal graded exercise test stages, using the 
Innocor™ device. This study also shows that cardiac output of recreationally trained cyclists does not change 
between these 2 points in time at 69, 77, and 85% peak power (Fig. 2). While stroke volume, too, is not different 
when determined at 46 and 103 s after power stage transitions, heart rate is higher after 103 than after 46 s at 
69% peak power, but is unchanged between the 2 measurement points in time at both 77 and 85% peak power. 
Our finding that at different power stages of standard graded cycling exercise tests, non-invasive measurements 
by inert gas rebreathing using the Innocor™ device can easily be performed in healthy, recreationally trained 
male cyclists, might offer a new dimension to current cardiovascular performance diagnostics. Since peak 
oxygen consumption is mainly determined by peak cardiac output (Fick 1870), and the latter mainly depends on 
a large stroke volume (Levine 2008), central haemodynamic improvements after training could be detected in 
parallel with gas exchange in future standard cardiovascular diagnostic tests. This possibility might prove useful 
in better defining the link between changes in metabolic demand and cardiovascular control following exercise 
and/or inactivity, and help physiologists as well as coaches to improve the supervision of athletic performance. 
Our result that at 69, 77, and 85% peak power, cardiac output in healthy male cyclists is the same at 46 and 103 
s after reaching the power stage (Fig. 2) lends further credence to earlier studies investigating the 
haemodynamic response to rest-to-exercise transitions. In these studies, it was shown that a steady state for 
cardiac output is attained between 30 (Lador et al. 2006, 2008) and 60 s (De Cort et al. 1991). Also, Davies et al. 
(1972) found a rapid adjustment of cardiac output after increasing power (i.e. walking velocity and gradient) 
during treadmill exercise, using a modified indirect Fick method. However, the observed halftime for cardiac 
output adaptation after increasing power from moderate (~40% maximum aerobic power) to heavy exercise 
(~80% maximum aerobic power) was 20 s. In our study, the respective halftime seems to be in the range of 12 s, 
indicating slightly faster cardiac output kinetics than Davies et al. (1972), although more measurement points in 
time would be required to obtain comprehensive kinetic data.  
We also observed that cardiac output in healthy male cyclists is the same at 46 and 103 s after reaching the 
power stage, irrespective of the size of the preceding power increment (up to 15% peak power) between stages 
(15% from 54 to 69% peak power, 8% from 69 to 77%, and 8% from 77 to 85%). Therefore, it seems that small 
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power increments (up to 15% peak power) between 2 stages may not influence the evolution of cardiac output 
on the higher stage, although we did not explicitly examine cardiac output on stages with equal power after 
increments of different sizes. Furthermore, the evolution of cardiac output after increasing power during a 
graded exercise test seems not to be influenced by a levelling off of cardiac output, which in our experiments 
occurred between 77 and 85% peak power. Our observed flattening of the cardiac output-power relationship at 
high submaximal intensities is in line with the findings of Calbet et al. (2007, dye-dilution) and Mortensen et al. 
(2005, Fick principle), who found cardiac output to level off after 84 and 80% peak power, respectively. 
Evidence for rapid adjustments of stroke volume after stage transitions is that stroke volume was not 
significantly different between 46 and 103 s at 69, 77, and 85% peak power. Furthermore, stroke volume at 69% 
peak power tended to be higher after 46 s than at 103 s. This finding was accompanied by a significantly lower 
heart rate. Since stroke volume was calculated by dividing cardiac output by heart rate, the lack of statistical 
significance concerning the potentially lower stroke volume at 103 s might be a statistical issue. This 
assumption may be supported by the data of Davis et al. (2005), who estimated stroke volume during graded 
exercise tests with different increment durations, i.e. 1 and 4 min.  They found that stroke volume at 
submaximal power was higher for the 1-min than for the 4-min protocol. However, the rapid inter-stage 
adjustment of stroke volume was not compromised by the levelling off of stroke volume between 69 and 85% 
peak power. In fact, in our experiments stroke volume increased significantly when transitioning from rest to 
69% peak power, but was the same at 69, 77, and 85% peak power. These findings are in line with those of 
Calbet et al. (2007), who reported stroke volume to rise after the transition from unloaded pedalling to 
submaximal exercise, and then reach maximal values beyond 64% peak power. Furthermore, our data confirm 
the findings of Davies et al. (1972), who found stroke volume to be similar between 40 and 80% of maximal 
aerobic power. However, according to our results, stroke volume might reach a plateau as late as at 77% peak 
power, since stroke volume tended to be lower at 69 compared to 77% of peak power. 
The encountered haemodynamic pattern leads us to speculate that at 69% peak power, maximal stroke volume 
may not be fully exploited. Thus, at this moderate intensity, stroke volume may still possess a reserve for further 
increases that could serve to quickly adjust cardiac output after increasing power by 15% from 54 to 69% peak 
power. The fact that at 69% peak power heart rate was different between 46 and 103 s may be further indicative 
of stroke volume's role in mediating the rapid adjustment of cardiac output after the stage transition from 54 to 
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69% peak power. Further support for our speculation that stroke volume might mediate the initial increase in 
cardiac output comes from De Cort et al. (1991), who reported that stroke volume quickly reacts to increases of 
power, and then tends to decrease after 90 to 120 s of constant power exercise, with cardiac output remaining 
unchanged. However, at exercise intensities of 77 and 85% peak power, peak stroke volume seems to be fully 
exploited. Accordingly, stroke volume at these intensities might not be further increased to raise cardiac output 
after power stage transitions. Therefore, cardiac output adjustments after increasing power from 77 to 85% peak 
power may solely rely on the increase in heart rate. Indeed, our data indicate that heart rate at 77 and 85% peak 
power is the same at 46 and 103 s. The quicker heart rate adjustment at high intensities may possibly be 
facilitated by the pronounced increase of sympathetic nervous system activity above 60-70% peak oxygen 
consumption (Nakamura et al. 1993; Saito and Nakamura 1995; Yamamoto et al. 1991) with concomitant 
pronounced increases of norepinephrine and epinephrine concentrations (Escourrou et al. 1984; Nakamura et al. 
1993; Orizio et al. 1988). This positive inotropic effect of the increased sympathetic drive to the heart is likely 
not to further raise stroke volume, since at 77 and 85% peak power maximal stroke volume was reached. 
 
Methodological considerations 
Three methodological issues must be considered. The first one concerns the rebreathing points in time (46 ± 7 
and 103 ± 5 s). They result from averaging the individual points in time (Table 2) across all participants, and are 
explained by the fact that the point in time of the first breath, of which the end-tidal nitrous oxide concentration 
was used for fitting the regression line, slightly varied between participants as well as within participants 
between the tests. Two reasons explain this variation. The first reason is that the point in time of complete gas 
mixing (respiratory tracts, anaesthesia bag, mask, and valves) during inert gas rebreathing by Innocor™ slightly 
differed within the tests (within and between the participants). In our study, complete gas mixing was typically 
achieved within the first 3-5 breaths after the start of the rebreathing procedure. Complete gas mixing is required 
for reliably calculating pulmonary blood flow (from which cardiac output is determined), since the calculation 
of pulmonary blood flow is based on a regression line through end-tidal nitrous oxide concentrations vs. time. 
The second reason for the variation of the individual rebreathing points in time is, that depending on the 
participants' breathing pattern, the start of the rebreathing procedure varied by 1-5 breaths (within and between 
the participants). Hence, based on these individual measurement delays, the rebreathing points in time (averaged 
within and between the participants) were 46 and 103 s. The second methodological issue concerns a possible 
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measurement bias which might be caused by recirculation of nitrous oxide. In our experiments, the rebreathing 
manoeuvres at 103 s did not lead to nitrous oxide gas recirculation at 46 s. Thus, time intervals of approximately 
60 s between measurements point in time (and thus stage durations lasting 60 s) seem to be safe. However, for 
time intervals below 60 s, recirculation of nitrous oxide cannot be excluded. The third methodological 
consideration concerns the power stages, at which we performed the rebreathings (69, 77, and 85% peak power). 
These 3 power stages, corresponding to moderate to high exercise intensity levels before and after a hypothetic 
levelling off of cardiac output (Mortensen et al. 2005), were chosen because we speculated that a levelling off 
could influence the intra-stage adaptation of cardiac output and stroke volume. Furthermore, increments 
corresponding to 8% peak power were chosen because this value represents approximately 30 W increments in 
graded exercise tests performed by experienced male road cyclists (Amann et al. 2004). 
 
We conclude that during standard graded exercise tests, the determination of cardiac output and stroke volume 
by Innocor™ inert gas rebreathing at moderate to high submaximal power outputs in healthy, recreationally 
trained male cyclists is easily feasible for performance diagnostics purposes. Furthermore, our results indicate 
that during standard graded exercise tests the haemodynamic response to power stage transitions from 54 to 
69%, 69 to 77%, and 77 to 85% peak power is fast enough to ensure same values of cardiac output and stroke 
volume at 46 and 103 s on the higher stage. Due to this rapid adjustment of cardiac output, stage durations 
lasting less than 60 s are possible. Finally, since power increment sizes of 8 and 15% at submaximal levels seem 
not affect intra-stage adjustments of cardiac output on the higher stages, these power increments may be well 
suited to assess submaximal cardiac output during graded exercise tests. 
 
Acknowledgments: We thank Mr Manuel Koller, Seminar for Statistics, ETH Zurich, for his assistance with 
statistical analyses.  
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TABLES AND FIGURES 
Table 1 Values of body mass, height, age, peak oxygen consumption, and peak power for 16 male cyclists. SD, 
standard deviation. 
 
Table 2 Individual rebreathing points in time (s) after exercise-to-exercise transitions at 69, 77, and 85% peak 
power for 16 male cyclists. SD, standard deviation. 
 
Table 3 Cardiac output, stroke volume, heart rate, and oxygen consumption at rest, 69, 77, and 85% peak 
power. During exercise, measurements were performed at 46 and 103 s after the exercise-to-exercise transition. 
Data are means ± standard deviation for 16 male cyclists. We compared cardiac output, stroke volume, heart 
rate, and oxygen consumption between 46 and 103 s on each stage [P (46 vs. 103 s)], as well as between stages 
(P Rest vs. 69% peak power, P 69 vs. 77% peak power, P 77 vs. 85% peak power). 
 
Fig 1 Cardiac output measurement protocol (tests 2 and 3). Rebreathings were performed either at 46 or 103 s 
after the power stage transitions at 69, 77, and 85% peak power, as assessed during test 1. On each stage, the 
measurement point in time (46 or 103 s) was randomised (see horizontal black arrows). Vertical black arrows, 
cardiac output measurements; vertical dashed arrows, learning trials (rebreathings with ambient air, only before 
test 2). 
 
Fig 2 Individual values of cardiac output at 46 and 103 s at 69, 77, and 85% peak power for 16 male cyclists. 
The solid line indicates the line of identity. 
 
Participant Body mass (kg) Height (m) Age (y) Peak oxygen 
consumption 
(l·min-1)
Peak power (W)
1 62.5 1.611 25.3 4.48 360
2 71.6 1.750 22.1 4.40 390
3 76.0 1.877 22.2 4.39 390
4 69.5 1.775 26.5 4.60 390
5 84.4 1.902 22.3 4.68 390
6 74.7 1.820 26.1 3.98 370
7 70.7 1.830 22.1 4.40 400
8 70.2 1.778 26.9 4.11 400
9 70.8 1.815 22.4 4.71 430
10 66.9 1.792 25.4 4.54 370
11 74.8 1.795 26.9 4.38 373
12 73.9 1.866 28.3 4.45 400
13 65.8 1.745 26.9 4.05 348
14 71.2 1.795 30.4 4.43 350
15 68.0 1.785 22.5 4.47 403
16 68.9 1.880 30.1 4.36 375
Mean ± SD 71.2 ± 5.0 1.801 ± 0.069 25.4 ± 2.9 4.40 ± 0.21 384 ± 22
Table 1
Participant 46 s 103 s
1 38 119
2 52 104
3 36 97
4 36 96
5 37 98
6 46 97
7 45 104
8 52 107
9 45 104
10 64 101
11 46 106
12 50 103
13 50 104
14 50 104
15 49 105
16 48 98
Table 2
Average ± SD 46 ± 7 103 ± 5
Table 3
Rest 69% peak power 77% peak power 85% peak power
46 s 103 s P(46 vs. 103 s) 46 s 103 s
P
(46 vs. 103 s) 46 s 103 s
P
(46 vs. 103 s)
P 
(46 s)
P 
(103 s)
P 
(46 s)
P 
(103 s)
P 
(46 s)
P 
(103 s)
Cardiac output 6.4 ± 1.2 18.1 ± 2.1 18.2 ± 2.3 0.794 20.7 ± 2.6 21.0 ± 2.3 0.356 21.6 ± 2.4 21.8 ± 2.7 0.678 < 0.001 < 0.001 < 0.001 < 0.001 0.070 0.263
(l·min-1)
Stroke volume 91 ± 23 126 ± 18 123 ± 21 0.343 132 ± 18 131 ± 18 0.874 131 ± 17 131 ± 22 0.999 < 0.001 < 0.001 0.137 0.052 1.000 1.000
(ml)
Heart rate 72 ± 8 145 ± 7 149 ± 9 0.005 158 ± 7 161 ± 7 0.169 166 ± 9 168 ± 11 0.276 < 0.001 < 0.001 < 0.001 < 0.001 0.003 0.002
(beats·min-1)
Oxygen consumption 0.43 ± 0.08 3.33 ± 0.30 3.62 ± 0.27 < 0.001 3.77 ± 0.28 3.90 ± 0.28 0.071 4.07 ± 0.27 4.13 ± 0.33 0.430 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
(l·min-1)
Rest vs. 69% peak power 69 vs. 77% peak power 77 vs. 85% peak power
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